We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

News

31 Mar 21
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
Attachments:
PDF Version
31 Mar 21
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease
Attachments:
PDF Version
26 Mar 21
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline
Attachments:
PDF Version
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
Attachments:
PDF Version
16 Mar 21
AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine
Attachments:
PDF Version
09 Mar 21
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases
Attachments:
PDF Version
24 Feb 21
AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference
Attachments:
PDF Version
17 Feb 21
AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference
Attachments:
PDF Version
11 Feb 21
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
Attachments:
PDF Version
08 Feb 21
AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease
Attachments:
PDF Version
29 Jan 21
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
Attachments:
PDF Version